{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-324768","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.573033+00:00","generated_at":"2026-05-16T12:46:33.957570+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vor Bio raises $150M in private placement; appoints two new directors","bullets":["Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.","New/existing investors include RA Capital, Forbion, Frazier Life Sciences, Caligan, Logos, Venrock.","Proceeds to advance telitacicept Phase 3 trials for myasthenia gravis and Sjögren's disease.","Director Sarah Reed resigned; Andrew Levin (RA Capital) and Wouter Joustra (Forbion) appointed.","Levin and Joustra receive standard director fees and option grants of 3,000 shares each."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-324768","json":"https://secwatch.observer/filing/0001193125-25-324768.json","markdown":"https://secwatch.observer/filing/0001193125-25-324768.md","text":"https://secwatch.observer/filing/0001193125-25-324768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/vor-20251215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:46:33.957570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f3bc9c61e8759b1438a048febbc29c419f5ba85","claim":"Vor Biopharma Inc. issued 13,876,032 shares of common stock to institutional and accredited healthcare specialist investors for $10.81 per share, gross proceeds approximately $150 million.","evidence_excerpt":"Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm","confidence":0.98,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"13,876,032 shares"},{"label":"Purchaser","value":"institutional and accredited healthcare specialist investors"},{"label":"Consideration","value":"$10.81 per share, gross proceeds approximately $150 million"}],"fact_type":"equity_issuance"},{"claim_id":"19b9ce0aa64d8ac77de148153a5d8c652f6636a4","claim":"Vor Biopharma Inc. entered into Securities Purchase Agreement with certain investors valued at 13,876,032 shares of common stock at $10.81 per share for gross proceeds of approximately $150.0 mil (effective 2025-12-15).","evidence_excerpt":"On December 15, 2025, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 13,876,032 shares (the “Shares”) of the Company’s common stock, at a price per Share of $10.81, for gross proceeds of approximately $150.0 million (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"13,876,032 shares of common stock at $10.81 per share for gross proceeds of approximately $150.0 mil"},{"label":"Effective","value":"2025-12-15"}],"fact_type":"material_agreement"},{"claim_id":"9ee4892b585ac29031b874796ea708ca20fb3a44","claim":"Vor Biopharma Inc. entered into Registration Rights Agreement with certain investors valued at Company obligated to file S-3 registration statement within 45 days of closing and use best efforts (effective 2025-12-15).","evidence_excerpt":"In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated December 15, 2025 (the “Registration Rights Agreement”), with the Investors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm","confidence":0.97,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"Company obligated to file S-3 registration statement within 45 days of closing and use best efforts"},{"label":"Effective","value":"2025-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}